Vertex Pharma (VRTX) Posts Smaller Q4 Loss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Needham & Company Downgrades Vertex (VRTX) to Hold
January 29, 2015 7:54 AM ESTNeedham & Company downgraded Vertex (NASDAQ: VRTX) from Buy to Hold.
Analyst Alan Carr commented, "Vertex reported 4Q14 financial results yesterday after market close. WW Kalydeco 4Q14 sales were $124.4M (+14% y/y). The company pre-announced net sales of approximately $120M earlier this... More
Maxim Group Downgrades Vertex (VRTX) to Hold
January 29, 2015 7:30 AM ESTMaxim Group downgraded Vertex (NASDAQ: VRTX) from Buy to Hold with a price target of $121.00 (from $148.00).
Analyst Jason Kolbert commented:
Vertex reported YE2014 non-GAAP revenue and operating expenses of $536M and $920M, respectively, and a non-GAAP loss of $511M and EPS of ($2.17). Revenue was driven largely by Kalydeco sales of $464M. Vertex enters 2015 with... More